Combined Analysis of Clinical Data on HGF Gene Therapy to Treat Critical Limb Ischemia in Japan.

CONCLUSIONS: The findings indicated that intramuscular injection of naked HGF plasmid tended to improve the resting pain and significantly decreased the size of the ischemic ulcer in the patients with CLI who did not have any alternative therapy such as endovascular treatment (EVT) or bypass graft surgery. An HGF gene therapy product, CollategeneTM , was recently launched with conditional and time-limited approval in Japan to treat ischemic ulcer in patients with CLI. Further clinical trials would provide new therapeutic options for patients with CLI.
PMID: 32416690 [PubMed - as supplied by publisher]

Source: Current Gene Therapy - May 15, 2020 Category: Genetics & Stem Cells Authors: Morishita R, Shimamura M, Takeya Y, Nakagami H, Chujo M, Ishihama T, Yamada E, Rakugi H Tags: Curr Gene Ther Source Type: research